Hospital
White River Health System, INC.
White River Health System, INC. was paid $3.30M by Medicaid between Jan 2018 and Dec 2024, across 122 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 12% of everything it billed.
33Billing provider infoWHITE RIVER HEALTH SYSTEM, INC.
MOUNTAIN VIEW, AR 72560
MOUNTAIN VIEW, AR 72560
33aNPI1417913419assigned 04/26/2006
33bProvider typeCritical Access Hospital
28Total paid$3.30M
24GClaims161,769
24DCodes billed122
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Arkansas
Rank by total paid#3 of 34
Median peer was paid$773K
This provider vs. median4.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BAXTER, SHAWNA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,393 | $457K | |
| 2019 | 26,731 | $619K | |
| 2020 | 27,245 | $471K | |
| 2021 | 25,055 | $527K | |
| 2022 | 23,433 | $487K | |
| 2023 | 22,677 | $432K | |
| 2024incomplete | 16,235 | $307K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 12% | 2,715 | 1,569 | $399K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 9.5% | 2,566 | 1,534 | $313K |
| 80053 | Comprehensive metabolic panel | 7.6% | 11,834 | 9,374 | $249K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.4% | 3,747 | 2,673 | $244K |
| 87631 | 5.0% | 1,444 | 1,386 | $166K | |
| 70450 | Computed tomography, head or brain; without contrast material | 4.8% | 1,861 | 1,566 | $159K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.0% | 3,364 | 916 | $133K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.8% | 1,414 | 1,231 | $125K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 721 | 655 | $104K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 3.0% | 2,176 | 2,001 | $99K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.9% | 3,145 | 2,199 | $96K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.7% | 1,248 | 1,087 | $90K |
110 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.2% | 12,844 | $71K |
| 36415 | Collection of venous blood by venipuncture | 1.7% | 16,761 | $57K |
| 99283 | Emergency room visit (moderate) | 1.7% | 3,626 | $57K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.6% | 4,141 | $53K |
| 71046 | Radiologic examination, chest; 2 views | 1.6% | 3,256 | $51K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.5% | 1,319 | $50K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.5% | 2,819 | $48K |
| 83880 | 1.2% | 2,536 | $38K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 4,592 | $38K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 373 | $30K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,061 | $30K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,371 | $29K |
| 84484 | <1% | 4,371 | $26K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 387 | $24K |
| 99284 | Emergency room visit (serious) | <1% | 2,632 | $23K |
| 81001 | <1% | 6,708 | $22K | |
| 87040 | <1% | 1,815 | $22K | |
| 85027 | <1% | 3,332 | $19K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,291 | $18K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 736 | $18K |
| 82553 | <1% | 2,246 | $17K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,383 | $17K |
| 82550 | <1% | 2,673 | $17K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,365 | $16K |
| 64493 | <1% | 71 | $16K | |
| 87077 | <1% | 1,428 | $16K | |
| 64635 | <1% | 51 | $14K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 94 | $14K |
| 62323 | <1% | 103 | $13K | |
| 81025 | <1% | 1,448 | $13K | |
| 96376 | <1% | 596 | $12K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 402 | $11K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,426 | $11K |
| 82150 | <1% | 1,396 | $11K | |
| 83690 | <1% | 1,302 | $10K | |
| 83735 | <1% | 2,008 | $10K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,426 | $10K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,051 | $9K |
| 80061 | Lipid panel | <1% | 908 | $9K |
| 82962 | <1% | 2,430 | $9K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 187 | $8K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 283 | $8K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 720 | $7K |
| 84145 | <1% | 812 | $7K | |
| 87186 | <1% | 1,332 | $7K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 30 | $6K |
| 99285 | Emergency room visit (most serious) | <1% | 745 | $6K |
| 87632 | <1% | 35 | $5K | |
| 80305 | <1% | 537 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,155 | $5K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 90 | $4K |
| 85610 | <1% | 1,517 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 589 | $4K |
| 83605 | <1% | 724 | $4K | |
| 85378 | <1% | 656 | $4K | |
| 82607 | <1% | 359 | $4K | |
| G0378 | Hospital observation service, per hour | <1% | 1,426 | $4K |
| 73630 | <1% | 128 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 97 | $4K |
| 71020 | <1% | 263 | $3K | |
| 97162 | <1% | 41 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 14 | $3K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 17 | $3K |
| 87070 | <1% | 235 | $3K | |
| 73562 | <1% | 68 | $2K | |
| 87807 | <1% | 213 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 330 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $2K |
| 87428 | <1% | 31 | $2K | |
| 87581 | <1% | 35 | $2K | |
| 87486 | <1% | 35 | $2K | |
| 87400 | <1% | 377 | $2K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 12 | $1K |
| 64494 | <1% | 57 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 45 | $1K |
| 87503 | <1% | 35 | $935.04 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 111 | $929.94 |
| 86757 | <1% | 51 | $927.04 | |
| 73030 | <1% | 51 | $854.41 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 982 | $774.99 |
| 86666 | <1% | 43 | $713.14 | |
| 73130 | <1% | 13 | $560.93 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 843 | $515.87 |
| 86617 | <1% | 37 | $498.36 | |
| 72110 | <1% | 12 | $495.80 | |
| 80050 | General health panel | <1% | 14 | $438.03 |
| 94760 | <1% | 33 | $343.56 | |
| 86668 | <1% | 37 | $334.94 | |
| J2704 | Injection, propofol, 10 mg | <1% | 791 | $322.81 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 23 | $317.80 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,328 | $312.03 |
| 74022 | <1% | 15 | $296.64 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 188 | $245.20 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 169 | $230.48 |
| 73610 | <1% | 14 | $218.00 | |
| 85652 | <1% | 29 | $212.90 | |
| 51702 | <1% | 24 | $196.00 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 23 | $181.17 |
| 82803 | <1% | 16 | $179.55 | |
| 64636 | <1% | 63 | $138.77 | |
| J3490 | Unclassified drugs | <1% | 30 | $110.85 |
| 86308 | <1% | 14 | $103.46 | |
| 85730 | <1% | 12 | $62.38 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 101 | $61.31 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 109 | $41.32 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 97 | $30.25 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 39 | $24.34 |
| T1502 | Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit | 0% | 118 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 69 | $0.00 |
| 36600 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBAXTER, SHAWNA (PROVIDER ENROLLMENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.